Human hybridomas producing a preselected human monoclonal antibody are prepared by fusing human lymphocytes with a hybrid fusion partner. The hybrid fusion partner is the result of fusing human lymphocytes with human myeloma cells at least once wherein the resulting hybrid cell is capable of being a functional human fusion partner.
A stable trioma cell line capable of secreting a non-human primate monoclonal antibody specific against a selected antigen. An exemplary cell line secretes chimpanzee monoclonal antibody specific against an antigen associated with hepatitis nonA/nonB infection. The cell line is produced, in the method of the invention, by isolating lymphocytes from a primate immunized with the selected antigen, and immortalizing the lymphocytes by fusion with a stable, non-antibody-secreting murine myeloma/human hybridoma cell line having selected-for human characteristics. The trioma fusion products are selected for secretion of the desired antibody, which has a variety of diagnostic and/or therapeutic uses.
A method of producing biologically active substances using a hybrid cell line obtained by fusing (1) a human tumor cell line which does not grow in a medium containing aminopterin or/and azaserine or cell line derived therefrom with (2) a human non-tumor macrophage. The human tumor macrophage cell line may be either a thymidine kinase-deficient cell line of U-937 or a thymidine kinase-deficient cell line of THP-1, the non-tumor macrophage may be alveolar macrophage, splenic macrophage, peripheral blood monocyte, peritoneal macrophage, hepatic macrophage, placental macrophage, or thymic macrophage, and the biologically active substance produced is a tumoricidal substance or interleukin-1.
Somatic cell hybrids of purely human origin are described that are suitable fusion partners for producing hybridomas by fusion with antibody producing cells, which hybridomas are stable and continuous.
Human-human hybrid cell lines that synthesize and secrete monoclonal antibodies against antigenic determinants on cancer cells, generated by fusing a human lymphoblastoid B cell line to human lymphocytes, and therapeutic and diagnostic uses of the monoclonal antibodies in both cancer treatment and research is disclosed.
Antibodies having binding affinity for two desired antigens, hereinafter "recombinant monoclonal antibodies"; recombinant monoclonal antibodies produced by a quadroma cell or a trioma cell; and methods for producing recombinant monoclonal antibodies by means of a quadroma cell or a trioma cell, wherein a quadroma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a hybridoma cell which produces an antibody having specific binding affinity for another desired antigen, and wherein a trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a lymphocyte which produces an antibody having specific binding affinity to another desired antigen.
